Vet-Stem, Inc. Founder and CEO Presents at TargetMeeting's 3rd World Drug Discovery Online Conference
Dr. Robert Harman, Founder and CEO of Vet-Stem, Inc., a Regenerative Veterinary Medicine company in Southern California, presented at TargetMeeting’s 3rd World Drug Discovery Online Conference, October 15-17th, 2013. Topics of the web-based conference covered biotechnology and biopharmaceuticals, gene and cell therapy, as well as research and clinical trials. Target Meeting is a leading online life science conference organizer that proudly does not require any travel from participants.
Participants like Dr. Harman were able to log into a secure conference track to hear live sessions, be part of question and answer forums, and give interactive presentations. Dr. Harman’s presentation was on "The Science and Business of Veterinary Regenerative Medicine," covering the use of stem cell therapy, types of stem cells, and uses in clinical veterinary medicine.
"Veterinary Regenerative Medicine is 'a discipline that seeks to replace or regenerate cells, tissue or organs, to restore or establish normal function.' Stem cell medicines have been used clinically in veterinary medicine in advance of clinical use in human medicine. There are many commercial companies already offering autologous services and allogeneic stem cell medicines globally." -Dr. Harman.
Dr. Harman explored the science and business of veterinary regenerative medicine, introducing first the two most commonly employed tissue sources of mesenchymal stem cells (MSC), which are adipose (fat) tissue derived stem cells, and bone marrow derived stem cells.
Dr. Harman also discussed the adoption of the value of the human-companion animal bond and the role of animals in improving human health, drawing from his decade of experience providing stem cell therapy for over 10,000 animals at his company, Vet-Stem. Dr. Harman covered the expansion of companies providing pet insurance, as well as the increasing numbers of pet owners who are older and without children at home have driven the demand for safe and effective veterinary stem cell therapy.
About Vet-Stem, Inc.
Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.’s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure.